Actively Recruiting
Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery
Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-05-14
235
Participants Needed
1
Research Sites
33 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.
CONDITIONS
Official Title
Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18-85 years old
- Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)
- All genders
You will not qualify if you...
- ASA Class V
- Urgent or emergent surgery
- Contraindications to Suzetrigine (e.g., use of strong CYP3A inhibitors)
- History of substance use disorder or chronic opioid use
- Reoperation
- Patient refusal or inability to consent
- Use of moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, Clarithromycin)
- Use of moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, Rifabutin)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mount Sinai Morningside
New York, New York, United States, 10025
Actively Recruiting
Research Team
H
Himani Bhatt, DO
CONTACT
M
Michael Lazar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here